Introduction
============

Tuberculosis (TB) remains a major global health problem, with an estimated 9 million incident cases and 1.5 million deaths in 2013 according to the World Health Organization (WHO)[@B1]. In Korea, the prevalence of bacteriologically or radiologically active TB (\>5 years old) decreased dramatically from 5,168/100,000 persons in 1965 to 767/100,000 persons in 1995[@B2]. However, TB remains a current major health concern in Korea, since new cases have plateaued at approximately 100/100,000 persons over the past decade[@B3]. One possible explanation for the steady rate of new TB cases in Korea is an increasing proportion of the elderly, who may be at a higher risk for TB development[@B3]. TB also has the highest mortality rate among the infectious diseases; it was 4.9/100,000 persons in 2012[@B3][@B4][@B5][@B6][@B7]. In pulmonary TB patients, the mortality rate during TB treatment reached 3.4% in a recent multicenter study[@B8].

Current TB drugs were developed 40 years ago and have a high treatment success rate if patients take TB drugs throughout the course of treatment[@B9]. However, current regimens include many TB drugs and require lengthy treatment durations. Therefore, there are challenges in the current TB treatment such as shortening the treatment duration, increasing adherence, and managing adverse drug effects. This article covers current TB treatment in patients with newly diagnosed drug-susceptible pulmonary TB based on the Korean Guidelines for Tuberculosis, second edition, 2014[@B10] and recent clinical studies for TB treatment[@B8][@B11][@B12][@B13][@B14][@B15][@B16][@B17][@B18][@B19][@B20].

Principles of TB Chemotherapy
=============================

The overall goals for treatment of TB are (1) to cure the disease that could improve quality of life for individual patients, (2) to minimize transmission of *Mycobacterium tuberculosis* to other persons, and (3) to prevent a relapse of this disease and spread of drug-resistant TB[@B10][@B21].

*M. tuberculosis* has characteristics distinct from other bacteria, including slow growth, with generation times of 15 to 20 hours and a capacity for dormancy that requires prolonged treatment to confirm successful eradication[@B22]. Moreover, this organism can actively multiply in the liquid caseous debris of pulmonary cavities, which may contain up to 10[@B8] organisms [@B22]. Drug resistance could be achieved by random genetic point mutation; it is also possible that the large population of organisms in such cavities could have the potential for drug resistance[@B22]. Therefore, a combination of highly active agents against *M. tuberculosis* is needed for the successful eradication of these organisms in their various states, and for preventing drug resistance. However, the most important cause of TB therapy treatment failure is the development of drug resistance, which can be developed by irregular drug-taking, inadequate dosage, and single-drug treatment. Sufficiently long periods of TB treatment are also needed to eradicate the slow growing mycobacteria. Therefore, to achieve the overall TB treatment goal, the following principles should be followed: (1) combination therapy of more than three TB drugs for prevention of drug resistance, (2) once-daily administration of TB drugs and exact dosage for optimizing efficacy, and (3) taking TB drugs regularly for at least 6 months.

TB drugs are classified into five groups according to efficacy, potency, and drug class ([Table 1](#T1){ref-type="table"})[@B23]. First-line TB drugs comprising group 1-except streptomycin, which is classified with the other injectable agents in group 2-are the most potent, have the best tolerance of all TB drugs, and are currently recommended in a four-drug combination for the treatment of drug-susceptible TB. A lower degree of efficacy and a higher degree of intolerability and toxicity have limited the use of second-line TB drugs for patients with drug-resistant TB or intolerance with first-line drugs.

The standard short course regimen is a 2-month period of isoniazid (INH), rifampin (RIF), ethambutol (EMB), and pyrazinamide (PZA), followed by a 4-month period of INH, RIF, and EMB (2HREZ/4HR\[E\]). If the organism is susceptible to INH and RIF upon drug susceptibility testing, EMB can be discontinued. If PZA cannot be included in the initial phase of treatment, a combination of INH, RIF, and PZA should be administered for 9 months (9HRE).

The standard four-drug (2HREZ/4HR) regimen has shown high efficacy in achieving cure rates around 90%-95%, both in treatment under oversight of TB control programs and trial conditions[@B24]. A recent multicenter retrospective cohort study was conducted in Korea, including a total of 2,481 patients with pulmonary TB and excluding patients with treatment default, those who were transferred to another hospital, had unknown treatment outcome, and had positive human immunodeficiency virus antibodies; successful treatment was achieved for 2,333 patients (94%), who comprised those being cured (45.5%) and completing treatment (48.5%)[@B8]. However, the treatment success fate of all reported TB patients in Korea is still low, that is, less than 70%; this low success rate is mainly caused by patients with treatment default and for whom there is an unknown treatment outcome[@B5]. Therefore, to improve the treatment success rate in Korea, more efforts are necessary to reduce the number of patients with default and to improve the collection of accurate data regarding treatment outcomes in TB patients.

Optimal Duration of TB Treatment
================================

The relapse rates for standard 6-month treatment of pulmonary TB were 1%-2% at 24 months after treatment, although the current TB regimen showed high efficacy[@B25]. It has been recommended that patients with risk factors for relapse including cavitation on chest radiography, extensive disease, immunosuppression, and positive sputum culture at 2 months of treatment may need a treatment extension of up to 9 months[@B9]. However, the evidence regarding efficacy of treatment extension is weak and there are no defined criteria for prolonging treatment to prevent relapse of TB. In a recent study performed in Korea, the combination of cavitation on initial chest radiography and positive culture after 2 months was associated with an increased risk of 1-year relapse, with the authors suggesting a treatment extension in these patients[@B17]. However, this was a single center retrospective study that included only 6 patients with TB relapse, and there was no proven efficacy of prolonged TB treatment for preventing relapse of TB in these patients. Further studies are needed to evaluate the efficacy of extending standard treatments. In the Korean Guidelines for Tuberculosis, based on the previous study, in cases with cavitations on the chest radiograph at the start of treatment and a positive culture after 2 months of treatment, extending standard treatment may be considered, but the total duration of treatment should be individualized according to the patient\'s condition[@B10].

Shortening the treatment duration could be a big advancement in TB control. It could enhance adherence to TB treatment, decrease side effect rates, and reduce costs. A randomized, open-label equivalence trial evaluating the shortening of a standard treatment continuation period for 2 months (2 months of HREZ+2 months of HR) in patients with non-cavitary TB and negative sputum culture after 2 months showed significantly higher rates of relapse in a 4-month arm than a standard 6-month arm (7.0% vs. 1.6%; risk difference, 0.054; 95% confidence interval with Hauck-Anderson correction, 0.01-0.10)[@B26]. Failure to eradicate dormant bacilli in the use of current standard regimens might result in a higher relapse rate. Therefore, regimens successfully used to shorten the treatment duration need to focus on the introduction of new drugs with novel mechanisms of action[@B11]. Recently, three non-inferiority trials were performed to shorten standard therapy to 4 months using fluoroquinolones or higher doses of rifapentine ([Table 2](#T2){ref-type="table"})[@B11][@B12][@B13][@B14].

OFLOTUB, a randomized, open-label, controlled trial, compared the standard 6-month regimen (2HREZ/4HR) with a regimen in which gatifloxacin (400 mg once daily) was substituted for EMB during 4 months of treatment comprised of a 2-month intensive phase of gatifloxacin, INH, RIF, and PZA, followed by a 2-month maintenance phase of gatifloxacin, INH, and RIF (2GHRZ/2GHR)[@B14]. The primary endpoints at 24 months after the end of treatment were unfavorable outcomes including treatment failure, recurrence, and death or dropout during treatment, which did not meet the non-inferiority of the 4-month regimen compared to the standard regimen.

REMoxTB (a randomized, double-blind, placebo-controlled trial) is comparing standard 6-month therapy (control group) with two study groups: the INH group, in which EMB was replaced with moxifloxacin for 17 weeks, and the EMB group, in which INH was replaced with moxifloxacin for 17 weeks[@B12]. The primary outcome that included treatment failure or relapse within 18 months after randomization of this study also did not meet the non-inferiority of the 4-month trial regimens compared to the standard regimen. However, trial regimens showed a more rapid sputum-negative conversion in both solid and liquid culture media. There was no significant difference in the incidence of grade 3 or 4 adverse events, as reported in 127 patients (19%) in the INH group, 111 patients (17%) in the EMB group, and 123 patients (19%) in the control group.

RIFAQUIN (a randomized, controlled trial) compared the standard 6-month regimen with two other study regimens (4-month regimen: 2 months of daily EMB, moxifloxacin, RIF, and PZA followed by 2 months of twice-weekly moxifloxacin and rifapentine \[900 mg\]; 6-month regimen: 2 months of daily EMB, moxifloxacin, RIF, and PZA followed by 4 months of once-weekly moxifloxacin and rifapentine \[1,200 mg\])[@B13]. The 6-month regimen was as effective as the standard 6-month regimen, but the 4-month regimen was inferior to the standard.

Based on these three clinical trials, recommendations could not be made related to the use of fluoroquinolone and/or high-dose rifapentine-containing regimens in shortening the TB treatment duration by 2 months.

Fixed Dose Combination
======================

One of the most important causes for TB treatment failure or development of drug resistance is non-adherence to TB drugs. It is reported that 20% to 50% of patients with TB treatment fail to complete treatment, and the consequences contribute to prolonged therapy, drug resistance, and death[@B27]. To improve adherence for TB treatment, direct observed treatment (DOT) is recommended[@B21]. DOT includes provision of anti-TB drugs directly to the patient and observation for patient intake. When DOT is not available, fixed dose combinations (FDCs) might be expected to improve a compliance of TB treatment and reduce a risk of drug resistance by preventing inappropriate drug selection and treatment of a single regimen[@B23]. The WHO and the International Union against Tuberculosis and Lung Disease (IUATLD) have recommended the use of these drugs since 1994[@B28][@B29]. In a randomized study comparing FDCs and separate drugs, the use of FDCs is preferred because of the potential advantages associated with FDC administration compared with separate-drug formulations [@B15][@B18]. However, these results do not fully demonstrate the non-inferiority of the FDCs compared with separate drugs using strict pre-trial definitions at both 18 months post-randomization and 30 months after treatment initiation. Moreover, the efficacy of FDCs is still controversial owing to the decreased bioavailability of rifampicin in FDCs[@B30]. A recent meta-analysis showed a trend toward higher risk of treatment failure or relapse with FDCs (pooled relative risk, 1.28; 95% confidence interval, 0.99-1.7) compared with separate drugs; there was no evidence that FDCs could improve patient compliance for TB drugs[@B16]. Given the possible risks, additional studies evaluating the efficacy of FDCs are warranted.

Monitoring of Treatment Response and Definition of Treatment Outcome
====================================================================

All patients who received TB treatment are recommended to undergo regular monitoring, not only for observing the response to therapy but also for facilitating treatment completion, and identifying and managing adverse drug reactions[@B10][@B21][@B23]. Monthly monitoring of patient weight and accordingly adjusting TB drug dosage upon weight change is also recommended[@B10][@B23]. To monitor pulmonary TB patients, sputum smears and culture examinations are recommended at monthly intervals until two consecutive culture specimens are negative at the end of treatment[@B10][@B21]. However, the response using sputum studies has its limitations, particularly in patients with smear- and culture-negative pulmonary TB. In these patients, chest radiography can provide information on the treatment response, but this alone is not recommended for monitoring the treatment response in pulmonary TB patients due to non-responsive fibrotic lesions to TB treatment and possible other causes of lung infiltration such as lung cancer, pneumonia, bronchiectasis, and hemorrhage[@B10]. Chest computed tomography (CT) has been acknowledged to be a more sensitive and specific tool for pulmonary TB compared to chest radiography; it is suggested as an appropriate tool for evaluating treatment responses and complications during treatment[@B31][@B32][@B33][@B34][@B35][@B36]. However, in a recent study including 66 pulmonary TB patients who had chest CT scans before and after TB treatment, 50% of all patients had significant residual lesions in chest CT scans after TB treatment, although these lesions had no evidence of persistent activity or the possibility of early relapse during the median 15 months of follow-up[@B19].

The treatment outcome definitions were revised recently by WHO: \"default\" and \"transfer out\" were removed, and \"lost to follow-up\" and \"not evaluated\" were inserted[@B37]. Lost to follow-up included cases with no start of TB treatment in addition to cases with interrupting TB treatment for 2 consecutive months or more, and not evaluated included cases with unknown outcome in addition to cases where the patient was transferred to another treatment unit ([Table 3](#T3){ref-type="table"})[@B37].

Management of Common Adverse Effects
====================================

Current combination chemotherapy for curing TB requires a lengthy treatment duration, and many TB drugs are associated with a high incidence of adverse effects. Mild adverse effects such as minor rash with itch, non-gouty polyarthralgia, and mild gastrointestinal upset including nausea, vomiting, poor appetite, and abdominal pain can generally be managed with symptomatic therapy and changing the timing of the drug administration. However, in severe adverse effects such as drug-induced hepatitis, RIF induced severe immunologic reactions including thrombocytopenia, hemolytic anemia, acute renal failure, and thrombotic thrombocytopenic purpura, EMB-induced optic toxicity, and PZA-induced acute gouty arthritis, offending drugs should be discontinued[@B10][@B21].

Drug-induced hepatotoxicity is the most frequent adverse effect limiting the use of effective first-line TB drugs and inducing transfer to other TB drugs[@B38]. Alanine aminotransferase (ALT) level has been revised as more specific for drug-induced hepatotoxicity than aspartate aminotransferase, which can be also increased in abnormal conditions in muscle, heart, or kidney [@B38]. If the ALT level is more than three times the upper limit of normal with symptoms, or more than five times the upper limit of normal without symptoms, three of the first-line anti-TB drugs, INH, RIF, and PZA should be discontinued; other causes of hepatitis such as viral hepatitis A, B, and C should be evaluated, in addition to intake of drugs other than those for TB, herbal medications, and alcohol. After the ALT has decreased to less than two times the upper limit of normal, first-line drugs can be reinitiated one at a time. Underlying chronic liver diseases have been contributing risk factors for TB drug-induced hepatitis, and patients with this disease might receive less effective non-hepatotoxic second-line TB drugs[@B38][@B39]. However, the relative risks according to various etiologies of chronic liver disease such as hepatitis A, B, and C infections, and degree of liver cirrhosis on the development of drug-induced hepatitis have not been well studied. Research conducted in Korea to address these issues revealed that patients with hepatitis B or C seropositivity, or without advanced liver cirrhosis (Child-Pugh score less than B), could be used for standard short course regimens including INH and RIF[@B20][@B40][@B41].

Conclusion
==========

Since the distinctive characteristics of *M. tuberculosis* include acquired drug resistance, slow growth rates, and dormancy, TB treatment requires a combination of many TB drugs and a lengthy treatment duration. However, most patients with drug-sensitive TB could be cured by a highly effective standard short course regimen if patients received a full course of TB therapy. Therefore, a clinician\'s efforts regarding appropriate management of adverse drug effects and treatment response monitoring are needed to prevent drug interruption. Recently, new regimens such as late-generation quinolones and high-dose rifapentine-containing regimens have been administered to reduce the duration of TB treatment, but the results of these studies were not successful. Further studies using new drugs with novel mechanisms of action are critical for shortening the treatment duration.
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###### Groups, recommended dosage for daily administration, and adverse effects of tuberculosis drugs for adults[@B23]
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###### Comparisons of current trials which aimed to shorten duration of TB treatment
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^\*^Adjusted difference, experimental group-control group, percentage points (OFLOTUB, 95% CI; REMoxTB, 97.5% CI; RIFAQAUIN, 90% CI). TB: tuberculosis; ITT: intention-to-treat; Control: 2HREZ/4HR; G: gatifloxacin; H: isoniazid; R: rifampin; Z: pyrazinamide; NA: not applicable; INH: isoniazid; EMB: ethambutol; M: moxifloxacin; E: ethambutol; P: rifapentine; PM~2~: twice weekly moxifloxacin and rifapentine; PM~1~: once-weekly moxifloxacin and rifapentine; CI: confidence interval.

###### Revised definitions of treatment outcomes for drug-susceptible tuberculosis patients[@B37]
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Adopted from World Health Organization (2013). Definitions and reporting framework for tuberculosis, 2013 revision: WHO/HTM/TB/2013.2 (available from: [http://apps.who.int/iris/bit stream/10665/79199/1/9789241505345_eng.pdf](http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf)), with permission of World Health Organization[@B37].

TB: tuberculosis.
